Amivantamab IV

BIOLOGICAL2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Advanced or Metastatic Colorectal CancerCarcinoma, Non-Small-Cell Lung

Phase 1

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

RecruitingNCT05379595

Janssen Research & Development, LLCAdvanced or Metastatic Colorectal Cancer

Start: 2022-07-29End: 2030-10-31Target: 225Updated: 2026-07-06

Phase 2

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Active, not recruitingNCT06120140

Janssen Research & Development, LLCCarcinoma, Non-Small-Cell Lung

Start: 2024-02-16End: 2030-06-30Updated: 2026-07-06

Related Papers

Antitumor activity of amivantamab by consensus molecular subtypes in <i>RAS</i> / <i>BRAF</i> wild-type metastatic colorectal cancer: Secondary analyses from the phase 1b/2 OrigAMI-1 study.

Journal of Clinical Oncology2026-05-27

Amivantamab Monotherapy in Chemorefractory <i>RAS</i>/<i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

2026-04-21

Abstract CT216: OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic RAS/BRAF wild-type colorectal cancer

Cancer Research2026-04-17

Abstract CT217: OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer

Cancer Research2026-04-17

Abstract 1770: Differential <i>in vitro</i> activity of amivantamab, cetuximab, and panitumumab against EGFR ECD resistance mutations

Cancer Research2026-04-03

Amivantamab plus FOLFOX or FOLFIRI in <i>RAS/BRAF</i> wild-type metastatic colorectal cancer: Long-term follow-up from the phase 1b/2 OrigAMI-1 study.

Journal of Clinical Oncology2026-01-10

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.

2025-09-091 citations

Dermatologic prophylaxis and impact on patient-reported outcomes in first-line <i>EGFR</i> -mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial.

Journal of Clinical Oncology2025-05-281 citations

Amivantamab treatment and intra-tumoral gene expression and immune cell changes in refractory metastatic colorectal cancer (mCRC): Whole transcriptome RNA-sequencing analysis from the OrigAMI-1 study.

Journal of Clinical Oncology2025-05-281 citations

OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic <i>RAS/BRAF</i> wild-type colorectal cancer.

Journal of Clinical Oncology2025-05-281 citations

OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided <i>RAS</i> / <i>BRAF</i> wild-type metastatic colorectal cancer.

Journal of Clinical Oncology2025-05-28

Amivantamab with or without chemotherapy in right-sided metastatic colorectal cancer: Updated results from OrigAMI-1, an open-label, phase 1b/2 study.

Journal of Clinical Oncology2025-01-271 citations

Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.

Journal of Clinical Oncology2024-01-208 citations

A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer.

Journal of Clinical Oncology2023-01-24